The National Academies of Sciences, Engineering, and Medicine announced today that Harvey Fineberg, former president of the Institute of Medicine (now the National Academy of Medicine) and current president of the Gordon and Betty Moore Foundation, will serve as the chair of the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats.

Formed earlier this month, the National Academies’ Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats was assembled at the request of the White House Office of Science and Technology Policy and the Office of the Assistant Secretary for Preparedness and Response in response to the COVID-19 outbreak.

The National Academies of Sciences, Engineering, and Medicine and the National Science Foundation announced today the formation of a Societal Experts Action Network (SEAN) to connect social and behavioral science researchers with decision-makers who are leading the response to COVID-19. SEAN will respond to the most pressing social, behavioral, and economic questions that are being asked by federal, state, and local officials by working with appropriate experts to quickly provide actionable answers.

The novel coronavirus has been called “the great equalizer,” when in reality, it has only exacerbated health inequities that racial and ethnic minorities have experienced for decades.

Dr. Anthony Fauci steps out of the West Wing for a briefing on the novel coronavirus in the Rose Garden of the White House in March.; Credit: Mandel Ngan/AFP via Getty Images

The White House will not allow the leading immunologist on the coronavirus task force to testify to Congress next week, calling the request "counter-productive" to the administration's efforts to contain the virus.

Dr. Anthony Fauci's testimony had been requested by the House Appropriations Committee, as part of an investigation into the White House response to the COVID-19 pandemic.

A committee spokesman on Friday said the White House had blocked the doctor from appearing before the panel.

"The Appropriations Committee sought Dr. Anthony Fauci as a witness at next week's Labor-HHS-Education Subcommittee hearing on COVID-19 response. We have been informed by an administration official that the White House has blocked Dr. Fauci from testifying," spokesman Evan Hollander said in a statement.

Fauci has become one of the most well recognized experts in the administration's coronavirus response team, often speaking publicly during task force briefings, and at times, seeming to contradict statements made by President Trump.

"While the Trump Administration continues its whole-of-government response to COVID-19, including safely opening up America again and expediting vaccine development, it is counter-productive to have the very individuals involved in those efforts appearing at Congressional hearings. We are committed to working with Congress to offer testimony at the appropriate time," White House spokesman Judd Deere said in a statement.

This content is from Southern California Public Radio. View the original story at SCPR.org.

When "Offramp" host John Rabe's father, Bill, created the list at Lake Superior State University in Michigan he likely didn't know it would thrive nearly 40 years later.  As language evolves there should never be a shortage of words and phrases we want to "kick to the curb."

This morning on "AirTalk," I asked listeners to pick the ones they "hate on."  We got some good ones, including my overused "unpack," as in "let's unpack that idea."  Falling into word patterns can happen so subtly that we don't even know it until someone points it out.

My nomination for the list -- "it is what it is."   What are yours?

This content is from Southern California Public Radio. View the original story at SCPR.org.

Director Michael Apted (L) with Larry Mantle in the AirTalk studio.

This past Wednesday on "AirTalk," film director Michael Apted came in to talk with us about his eighth documentary in the series that's followed the lives of 13 people, beginning in 1964 when the kids were seven.  They've shared their stories with Apted every seven years, and he's clearly invested a lot of emotion into this project.

"56 Up" is wonderful for how it shows the mid-life evolution of the participants.  Apted includes scenes from earlier interviews, so that we see what aspects of today's 56-year-olds were present in childhood and what turns their lives have made over these years. 

"56 Up" is showing at the Nuart in West Los Angeles, and Apted will be doing Q-and-A at some of the screenings.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The engineered Dominguez Gap Wetlands in Long Beach filters stormwater and runoff from the Los Angeles River, then the water is siphoned under the river to a spreading ground to the west.; Credit: Sharon McNary/KPCC

Angelenos are used to looking up Heal the Bay's annual beach water quality report card each May as we search out the cleanest places to swim and surf.

Now, the environmental advocacy group is focusing on a new target — the often polluted water that flows into the ocean from the mountains and across the L.A. Basin.

In a first-ever report, it concludes the managers of 12 watersheds from Malibu to Long Beach are making too little progress toward cleaning up this major source of pollution in the Pacific.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: Courtesy Randy Newman

Read the full article at LAist

Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: /Jackie Ferrentino for NPR

A lot is at stake for students taking Advanced Placement exams, even in normal times. If you score high enough, you can earn college credit. It's also a big factor in college applications. But for some students, the idea of studying right now feels impossible.

"I'm constantly thinking about making sure my family doesn't get sick and I don't get sick," says Elise, a high school junior outside Boston. (We're not using her full name because she's worried about hurting her college applications.)

Concerns about the coronavirus have put most standardized tests, such as the SAT and ACT, on hold this spring. But AP exams are going forward with a new online format — and that's raising questions about fairness.

Elise, 17, says she spent months preparing for what is typically a three-hour, multiple-choice and essay-based exam; she was blindsided when she learned it will now be an online, 45-minute, open-response test.

"I have no idea what I'm going to get when I open that test," she says.

Elise was hoping the College Board, which administers AP exams, would cancel this year's exams, as it did the spring SATs. But since the tests are being offered, she says she feels she has to take them. She worries it would look bad on her college applications if she opted out.

For other students, just the idea of taking the exam at home is causing anxiety. Kayleen Guzman, 17, from Boston says it's hard to find peace and quiet in her house right now.

"Currently, it's me, my mom, my dog, my sister and my stepdad," she explains. "Sometimes I feel like it's too much chaos."

But Guzman is glad she still has the opportunity to take the AP exams at all this year. She says she worked hard in her two AP classes and she wants the chance to earn college credit.

However, it's still unclear how much credit colleges will give students for this year's exams.

"None of us would say that we are confident that a 3 or 4 or 5 on the AP exam this year means the exact same thing as a 3, 4 and 5 on the exam last year," says Harvard University's Andrew Ho, who studies the reliability of educational tests.

Ho says that because of the new format, this year's AP exams won't be measuring the same thing as previous years' exams. For one, the new tests will cover less material. And changing where kids take it — from a proctored classroom to their laptops at home — is a big deal. But Ho adds, "Just because it's not completely comparable doesn't mean the College Board and colleges, through their own policies, couldn't adjust."

Some colleges are already adjusting. The University of California system has come out explicitly to say it won't change the way it credits AP scores. Other colleges that didn't want to go on the record say they are planning to change their policies, but the details weren't ready to share just yet.

In a statement, College Board spokesperson Jerome White said the organization decided to move forward with AP testing to give motivated students the opportunity to earn college credit. He added that the organization is making "a significant financial investment" to make the exams available online, from cheating prevention software to helping students who may not have an Internet connection or access to a computer.

Still, some educators worry that those efforts won't be enough.

"This situation has created a lot of distraction," says Savannah Lodge-Scharff, an AP Physics teacher for Boston Public Schools. She argues that without in-person classes, many students won't be able to engage with the material in the same way. On top of that, financial stress means many of her students are juggling additional responsibilities, like taking care of siblings.

"I have some of my students who are working 40, 50, 60 hours a week at the grocery store right now in the fear their parents are going to be laid off," she explains.

And then there's the question of geographic equity. This year's exams will be administered at the same time worldwide, meaning students in Hong Kong will be up at midnight to take it.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Justin Timberlake and Anna Kendrick in Trolls World Tour.; Credit: Universal Pictures/Trolls World Tour (2020)

Larry Mantle and KPCC film critics Lael Loewenstein, Amy Nicholson and Charles Solomon review this weekend’s new movie releases and share some of their recommendations for movies and TV shows to discover, rediscover and binge-watch while you’re at home.

• "Trolls World Tour" on VOD (Vudu, FandangoNOW, AppleTV, Amazon Prime Video , Microsoft Store & more)

• "The Quarry" on VOD (FandangoNOW, Google Play, DirecTV On Demand)

• "A White, White Day" on The Frida Virtual Cinema

• "Away" on Laemmle's Virtual Cinema and Amazon Prime Video

• "Selah And The Spades" on Amazon Prime Video

• "The Booksellers" on VOD (Google Play) and virtual cinemas, including Laemmle's and The Virutal Frida Cinema

• "Endings, Beginnings" on VOD (iTunes and FandangoNOW)

• "Sergio" on Netflix

Want to see what our critics are watching and recommending you watch during stay at home? Click here to see a full list of our FilmWeek critics' favorite TV shows and films to binge-watch during COVID-19.

Guests:

Amy Nicholson, film critic for KPCC, film writer for The Guardian and host of the podcasts ‘Unspooled’ and the podcast miniseries “Zoom”; she tweets @TheAmyNicholson

Lael Loewenstein, KPCC film critic and film columnist for the Santa Monica Daily Press; she tweets @LAELLO

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Circus of Books storefront.; Credit: Netflix/Circus Of Books (2020)

Rachel Mason had, to a certain extent, the normal upbringing you’d imagine a family of five with small business owner parents would have. But in her documentary, ‘Circus of Books’, she pulls the curtain on the double-life her parents led as modest business owners and pillars of the LGBTQ community.

Karen and Barry Mason established West Hollywood’s Circus of Books on Santa Monica Boulevard in the 1980s. What seemed like an unassuming bookstore was actually a gay porn shop that became an institution in the LGBTQ community during a time when homosexuality was still largely unaccepted. The store was far from being a “bookstore with a circus theme”. The Los Angeles-based shop was the central hub for gay pornography around the country, once one of the main distributors for adult films. 

While the store was becoming a home for gay culture and pride, the Masons largely kept their business a secret from colleagues, friends, family, even their own children. It’s a central conflict that Rachel Mason explores throughout the film as the daughter of two shop owners caught between the pressures of maintaining a traditional family image and making a living as gay pornography distributors.

Today on FilmWeek, we’re joined by ‘Circus of Books’ director Rachel Mason for a conversation on her documentary and the experience of creating a film with her parents and their secret as the subject.

‘Circus Of Books’ is currently streaming on Netflix. For more on the film from LAist’s Mike Roe, click here.

Guest:

Rachel Mason, director of the Netflix documentary ‘Circus of Books’ and daughter of Circus of Books owners Karen and Barry Mason; she tweets @RachelMasonArt

This content is from Southern California Public Radio. View the original story at SCPR.org.

A still from "Spaceship Earth".; Credit: Neon/"Spaceship Earth" (2020)

Two months is a long time to be quarantined in one place. Just ask, well, pretty much anyone in the era of COVID-19. But imagine if you were quarantined for two years instead of two months, all in the name of science, and it was by choice!

In 1991, eight researchers did exactly that in Oracle, Arizona as part of a first-of-its-kind mission called BIOSPHERE 2. No, there was no failed BIOSPHERE 1 mission -- BIOSPHERE 1 is planet Earth. The mission’s goal was to create a living ecosystem inside a massive glass and steel facility to show that human life could be sustained in outer space. The idea was that whenever humanity finally did gain the ability to travel deeper into space and colonize another planet, a biosphere would need to be built first so that life could be sustained. But what started as a science experiment quickly evolved into a cultural phenomenon, and while some watched with bated breath to see whether the researchers could really create a living ecosystem in a controlled environment, others saw the project and those who were involved as a cult of sorts. Director Matt Wolf explores BIOSPHERE 2  the researchers (“biospherians”) who carried the mission out, what ultimately happened and the good and bad ways in which it became a cultural phenomenon.

Today on FilmWeek, “The Frame” host John Horn talks with Wolf about the making of the film and what can be learned from the biospherians about our current situation staying at home because of COVID-19.

Guest:

Matt Wolf, director of the documentary “Spaceship Earth"

This content is from Southern California Public Radio. View the original story at SCPR.org.

Qualys BrowserCheck is a cloud service that makes sure your browser and installed plugins are all up-to-date so that you not affected by security vulnerabilities in outdated browser technology. [...]

Apple Senior Vice President of Worldwide Marketing Phil Schiller announces the new iPhone 6 during an Apple special event at the Flint Center for the Performing Arts on September 9, 2014 in Cupertino, California. Apple unveiled the two new iPhones the iPhone 6 and iPhone 6 Plus.; Credit: Justin Sullivan/Getty Images

Apple's latest mobile operating system — iOS 8 — is now available, and with it, a new technical hurdle for law enforcement. The company says it will be technologically impossible to access data on phones and iPads running iOS 8, because it won't allow user passcodes to be bypassed.

Our phones, of course, contain troves of information — contacts, messages, recordings — which can be helpful for investigative or prosecutorial purposes. The Supreme Court earlier this year ruled law enforcement cannot access that kind of data without a warrant. Prosecutors had already feared the warrant hurdle would be too much — Rockland County, N.Y., District Attorney Thomas Zugibe told the Wall Street Journal in June that technology "is making it easier and easier for criminals to do their trade," while the court "is making it harder for law enforcement to do theirs."

Now, even with a warrant, data from Apple devices running iOS 8 will be tough — and, Apple says, impossible — for law enforcement to get its hands on.

As The Washington Post reports, the move "amounts to an engineering solution to a legal quandary: Rather than comply with binding court orders, Apple has reworked its latest encryption in a way that prevents the company — or anyone but the device's owner — from gaining access to the vast troves of user data typically stored on smartphones or tablet computers."

Not so fast, writes an iOS forensics expert, Jonathan Zdziarski. Just because Apple will no longer help police doesn't mean police can't find ways to use existing commercial forensics tools to extract the data themselves. Wired Magazine describes how Zdziarski proved his own point:

Zdziarski confirmed with his own forensics software that he was still able to pull from a device running iOS 8 practically all of its third-party application data — that means sensitive content from Twitter, Facebook, Instagram, web browsers, and more — as well as photos and video. The attack he used impersonates a trusted computer to which a user has previously connected the phone; it takes advantage of the same mechanisms that allow users to siphon data off a device with programs like iTunes and iPhoto without entering the gadget's passcode.

"I can do it. I'm sure the guys in suits in the governments can do it," says Zdziarski.

And, Apple will still be able to turn over user data stored outside its phones, for example, on its iCloud service, The Washington Post notes. Users often back up photos, videos, emails and more to iCloud, as the recent nude photo theft reminded us.

Apple, in creating plausible deniability for itself, is also using its strongly worded new privacy stance as a marketing opportunity. It's reinforcing what it says is a commitment to privacy and transparency when it comes to government data requests. Apple says so far this year, it has received fewer than 250 government requests for data, including requests to unlock encrypted iPhones.

Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Shares of Tronox Holdings traded higher after the company released preliminary Q1/20 earnings data and provided an update on its ongoing operations.

Full Text:

The molecular mechanism used by many bacteria to kill neighboring cells has redundancy built into its genetic makeup, which could allow for the mechanism to be expressed in different environments, say researchers at Penn State and the University of Wisconsin-Madison. Their new study provides insights into the molecular mechanisms of competition among bacteria. "Many organisms, including humans, acquire bacteria from their environment," said Tim Miyashiro, a biochemist and molecular biologist at Penn State and the leader of the research team. "These bacteria can contribute to functions within the host organism, like how our gut bacteria help us digest food. We're interested in the interactions among bacteria cells, and between bacteria and their hosts, to better understand these mutually beneficial symbiotic relationships." Cells of the bioluminescent bacteria Vibrio fisheri take up residence in the light organ of newly hatched bobtail squid. At night, the bacteria produce a blue glow that researchers believe obscures a squid's silhouette and helps protect it from predators. The light organ has pockets, or crypts, in the squid's skin that provide nutrients and a safe environment for the bacteria. "When the squid hatches, it doesn't yet have any bacteria in its light organ," said Miyashiro. "But bacteria in the environment quickly colonize the squid's light organ." Some of these different bacteria strains can coexist, but others can't. "Microbial symbioses are essentially universal in animals, and are crucial to the health and development of both partners," says Irwin Forseth, a program director in the National Science Foundation's Division of Integrative Organismal Systems, which funded the research. "The results from this study highlight the role small genetic changes can play in microbe interactions. Increased understanding will allow us to better predict organisms' performance in changing environments."

Image credit: Andrew Cecere

Full Text:

A new study shows that graphene sheets can block the signals mosquitoes use to identify a blood meal, potentially enabling a new chemical-free approach to mosquito bite prevention. Researchers showed that multilayer graphene can provide a twofold defense against mosquito bites. The ultra-thin yet strong material acts as a barrier that mosquitoes are unable to bite through. At the same time, experiments showed that graphene also blocks chemical signals mosquitoes use to sense that a blood meal is near, blunting their urge to bite in the first place. The findings suggest that clothing with a graphene lining could be an effective mosquito barrier.

Image credit: Hurt Lab/Brown University

Full Text:

National Science Foundation (NSF)-funded researchers from North Carolina State and Elon universities have developed a technique that allows them to remotely control the movement of soft robots, lock them into position for as long as needed and later reconfigure the robots into new shapes. The technique relies on light and magnetic fields. "By engineering the properties of the material, we can control the soft robot's movement remotely; we can get it to hold a given shape; we can then return the robot to its original shape or further modify its movement; and we can do this repeatedly. All of those things are valuable, in terms of this technology's utility in biomedical or aerospace applications," says Joe Tracy, a professor of materials science and engineering at NC State and corresponding author of a paper on the work. In experimental testing, the researchers demonstrated that the soft robots could be used to form "grabbers" for lifting and transporting objects. The soft robots could also be used as cantilevers or folded into "flowers" with petals that bend in different directions. "We are not limited to binary configurations, such as a grabber being either open or closed," says Jessica Liu, first author of the paper and a Ph.D. student at NC State. "We can control the light to ensure that a robot will hold its shape at any point."

Image credit: Jessica A.C. Liu

Full Text:

Bridges make travel faster and more convenient, but, in an earthquake, these structures are subject to forces that can cause extensive damage and make them unsafe. Now civil and environmental engineer Petros Sideris of Texas A&M University is leading a National Science Foundation (NSF)-funded research project to investigate the performance of hybrid sliding-rocking (HSR) columns. HSR columns provide the same support as conventional bridge infrastructure columns but are more earthquake-resistant. HSR columns are a series of individual concrete segments held together by steel cables that allow for controlled sliding and rocking. This allows the columns to shift without damage, while post-tensioning strands ensure that at the end of an earthquake the columns are pushed back to their original position. Conventional bridges are cast-in-place monolithic concrete elements that are strong but inflexible. Structural damage in these bridge columns, typically caused by a natural disaster, often forces a bridge to close until repairs are completed. But bridges with HSR columns can withstand large earthquakes with minimal damage and require minor repairs, likely without bridge closures. Such infrastructure helps with post-disaster response and recovery and can save thousands in taxpayer dollars. In an earthquake, HSR columns provide "multiple advantages to the public," Sideris said. "By preventing bridge damage, we can maintain access to affected areas immediately after an event for response teams to be easily deployed, and help affected communities recover faster. In mitigating losses related to post-event bridge repairs and bridge closures, more funds can be potentially directed to supporting the recovery of the affected communities." According to Joy Pauschke, NSF program director for natural hazards engineering, "NSF invests in fundamental engineering research so that, in the future, the nation's infrastructure can be more resilient to earthquakes, hurricanes, and other forces of nature."

Image credit: Texas A&M University

US-based fintech Namogoo will integrate incentive platform

Source: Streetwise Reports   04/23/2020

Global healthcare packaging components manufacturer company West Pharmaceutical Services Inc. (WST:NYSE) today announced financial results for its first quarter ending March 31, 2020 and provided updated full-year 2020 financial guidance.

The company reported that net sales in Q1/20 increased to $491.5 million, a 10.8% increase from $443.5 million in Q1/19. During the same corresponding period, the firm stated that non-GAAP diluted earnings per share (EPS) increased by 36% to $0.99 and non-GAAP adjusted-diluted EPS increased by 36% to $1.01.

West Pharmaceutical Services advised that it is maintaining its FY/20 net sales guidance, which is expected to be in a range of $1.95-1.97 billion. The company stated that it is updating FY/20 adjusted-diluted EPS guidance to a new range of $3.52-3.62, compared to the prior estimated range of $3.45-3.55.

The company's President and CEO Eric M. Green commented, "During these unprecedented times, our priorities are focused on the well-being and safety of our team members as well as ensuring the supply of critical, high-quality components and solutions to our customers...I am extremely pleased that we delivered a strong performance in the first quarter given the challenging environment that the COVID-19 pandemic has had on our customers, our suppliers and our team members. In particular, we continued to deliver strong sales growth in high-value products, as demand trends from our worldwide customer base were similar to trends we saw last year. Our teams are partnering with a broad range of customers working to support efforts to develop solutions that address the global COVID-19 pandemic such as diagnostics, anti-viral therapeutics and vaccines."

The firm outlined sales in the most recent quarter by product line. The company reported that in Q1/20, net sales in its Proprietary Products segment grew by 9.7% to $373.5 million and that this segment "saw good demand for Westar^®, Daikyo^®, NovaPure^® and FluroTec^® components as well as for devices such as Daikyo Crystal Zenith^® syringes and cartridges and our self-injection platforms."

The firm noted that net sales from its Contract-Manufactured Products segment grew by 14.5% to $118.1 million led by sales of components for diagnostic devices and drug-injection delivery devices.

The company added that the Biologics market unit enjoyed double-digit organic sales growth, the Generics market unit achieved high-single digit organic sales growth and the Pharma market unit registered mid-single digit organic sales growth.

The firm additionally noted that during Q1/20 under its share repurchase program, it repurchased 761,500 shares for $115.5 million at an average share price of $151.65.

West Pharmaceutical Services is headquartered in Exton, Pa., roughly 35 miles west of Philadelphia, and is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.

West Pharmaceutical has market capitalization of around $13.5 billion with approximately 73.84 million shares outstanding. WST shares opened 5.25% higher today at $179.05 (+$8.93, +5.25%) over yesterday's $170.12 closing price and reached a new 52-week high price this morning of $190.27. The stock has traded today between $177.13 and $190.27 per share and is currently trading at $187.04 (+$17.17, +10.11%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: WST:NYSE, )

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19.

A recap of Parsley Energy's Q1/20 performance and projections for this year and next are given in a Raymond James report.

Shares of ION Geophysical traded higher after the company reported Q1/20 financial results that included a 53% year-over-year increase in revenue.

A new analysis of how to encourage pro-environmental behaviour highlights four effective techniques: goal-setting, prompts or reminders, witnessing the behaviour of others and introducing new behaviours that correspond with existing beliefs.

Global air quality will significantly deteriorate by 2050 unless further steps are taken to cut current emissions from human activities, according to recent research. Most people around the world will be affected by worsening air quality with hotspots of particularly poor air occurring in China, northern India and the Middle East.

The global production, trade and use of goods and services has a significant impact on the environment — and rates of consumption are rising. A new study combines two assessment methods to quantify the impact of European trade on the environment. It finds that, overall, the EU was a net importer of environmental impact from 2000 to 2010, that machinery, equipment and vehicles contributed most to the EU’s export impacts and that the EU’s trade balance (import impact minus export impact) is increasing over time. The two assessment methods complement one another well and could form the basis for future country or region-wide studies, suggest the researchers, by enabling a detailed analysis of individual steps within a product’s trade flow, while also providing a larger picture of the overall process.

There is a need to broaden the debate on sustainable food security from a straight comparison between organic and conventional farming to a consideration of a variety of farming techniques. This is the conclusion of a new review of research that indicates, for some crop types, organic yields can nearly match conventional yields under good management practices and growing conditions.

New research has produced a starch-based bioplastic with similar properties to equivalent traditional oil-based plastics. By adding an ammonium salt to thermoplastic starch (TPS) the study demonstrated an improvement in the plasticisation process, rendering it flexible, mouldable and potentially recyclable.

Staff in buildings that have been certified as ‘green’ under the LEED scheme are just as satisfied with their indoor working environment as people working in non-LEED buildings, according to research on commercial buildings. The study suggests that investment in the thermal and acoustic aspects of buildings, however, would further improve occupant satisfaction.

Misreported fishing catches in the Baltic Sea have probably led to incorrect fishing quotas, new research suggests. The study found that total catches between 1996 and 2009 have been underestimated for a significant period, skewing quota calculations.

A new analysis of how to encourage pro-environmental behaviour highlights four effective techniques: goal-setting, prompts or reminders, witnessing the behaviour of others and introducing new behaviours that correspond with existing beliefs.